Device Trial Radar · NCT02095691
RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 2013
Primary completion
Mar 2014
Study completion Apr 2015
Sponsor
- Lead sponsor
- Biosense Webster, Inc.Public (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 26, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, non-randomized, feasibility study to assess the safety and effectiveness of renal artery sympathetic denervation using the investigational devices in subjects with resistant hypertension.
Conditions
- Hypertension, Renal
Interventions
Celsius® ThermoCool® Renal DenervationDevice
The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure.Time frame: 30 days post-procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.